However, these modalities do not work specifi cally on biofi lms, whereas surgical or sharp debridement does and is much quicker.
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Biofi lm
Chronic wounds are mired in a chronic infl ammatory state exhibiting markedly elevated pro-infl ammatory cytokines (interleukin-1, tumour necrosing factor-alpha, gamma interferon), elevated matrix metalloproteases (MMP2, MMP8, MMP9) and excessive neutrophils. [10] [11] [12] [13] [14] This persistent infl ammatory state may be explained as the consequence of biofi lm phenotype bacteria -namely, chronic infection. 15 Although methods to detect and characterise biofi lm in wounds are only now being developed and tested for sensitivity, recent unpublished work by our laboratory is showing that over 80% of all chronic wounds evaluated have biofi lm phenotype bacteria and only wounds that are on a positive healing trajectory and are being treated with biofi lm-based wound care do not have detectable biofi lm phenotype bacteria (Dowd et al., unpublished data).
Our previous papers have explored the ecology, nature and physiological effects of biofi lm in wounds, 15 ,16 so we will not repeat this here.
Biofi lm-based wound care
Biofi lms are a wound management challenge for four main reasons:
• They are resistant to antibiotics (50 to 1500 fold) 17 • They are highly resistant to biocides (hydrogen peroxide, acids, bleach) 18 • They evade the host immune system (white blood cells, antibodies, complement) 19, 20 • They are poorly penetrated by many antibiotics used. [21] [22] [23] [24] Physical removal and suppression of biofi lm reformation is therefore a necessary part of the wound management regimen. Experience and the literature have demonstrated that debridement is the most effective modality to achieve this. [25] [26] [27] [28] Debridement can also facilitate an opportunity for antibiotic intervention: it physically disrupts the biofi lm, which then must reconstitute itself. To do this, the biofi lm has to reattach to the host surface, becoming metabolically active. This increases the rate of proliferation and synthesis, in turn increasing nutrient uptake. This presents a healing window of opportunity for clinicians as biofi lm phenotypes are much more susceptible to antibiotics and biocides in the fi rst 24-72 hours (depending on community species) due to energy and nutrient expenditure in the growth phase and the immaturity of the protective extracellular polymeric substance (EPS) matrix.
Although debridement can remove the vast majority of biofi lm phenotype bacteria, complete sterilisation of an active wound is unlikely, even with the most vigorous debridement, as bacteria have been shown to integrate around deep capillaries 29 and, based on both in vitro within 24 hours 30 and in vivo within 48 hours 31 evidence, extensive biofi lm can reform in wounds very rapidly.
To take advantage of the healing wound, advanced and rapid diagnostic methods are required to identify the bacteria and their potential antibiotic susceptibilities. These diagnostic methods are now being utilised effectively in our clinic. 32 Thus, a powerful combination of debridement, rapid molecular diagnosis of infecting agents, topical application of treating agents, and systemic antibiotics give a multiple concurrent strategy that we are fi nding to highly benefi cial clinically.
As well as physically removing biofi lm, temporarily disrupting its colony defences and forcing it to become more susceptible to antibiotics, biocides and host immunity, 17 ,18 debridement will also prepare the wound bed by opening all undermining and tunnels, removing all devitalised and poorly perfused tissue, and shaping the wound topography. The resulting smooth, well-perfused wound bed will inhibit biofi lm adhesion. Maintenance debridement prevents re-establishment.
However, complete eradication of biofi lm with debridement is not possible. Continued maintenance debridement is able to keep wound biofi lm in a weakened and susceptible state. In this illustration, which is based on our clinical model for wound care, maintenance debridement alone keeps the wound balance in favour of the host (healing) for approximately 43% of the days between visits, although the rate of healing immediately post-debridement is more rapid. However, in this scenario, the wound is capable of regressing in 57% of the days between visits as the balance shifts back to favour the biofi lm. When debridement is combined with multiple concurrent strategies to further inhibit the biofi lm's recovery, the healing window (clinical opportunity) remains open for 86% of the days between visits; furthermore, the net rate of healing is also augmented. In this multiple concurrent strategy, only 14% of the days between visits are capable of regression.
While these are not absolute numbers relative to every wound, the order and separation of the rates for single versus multiple concurrent biofi lm strategies are in alignment with what we see in the clinic. Regardless, the primary intent of Fig 1 is to illustrate the strategy of biofi lm-based wound care in a multifaceted approach; this maximises the wound's healing potential.
Cost-effectiveness
The premise of this article is that debridement is pivotal to chronic wound healing. It represents a minor portion of the total US wound-care budget: $188 million dollars in 2005, less than 0.8% of the total amount spent on wounds. 33 It has also been demonstrated, both scientifi cally and experientially, to decrease back-end costs such as antibiotics, hospitalisation, amputation and death.
8, 16 In rela- The goal of biofi lm-based wound care is to ensure the therapy maintains its balance within the healing window, as described in the text. It can be assumed from this fi gure that, without concurrent strategy, the frequency of debridement could be increased to keep the wound from falling below the healing stall point. Debridement remains the primary tool for ensuring the wound stays above the stall point tion to the expense of other treatments that have not been proven as broadly effective, 34,35 debridement would appear to be the most cost-effective option.
Conclusion
Biofi lm is an important, and until recently, an unrecognised barrier to chronic wound healing. Clinical experience demonstrates that frequent disruption of biofi lm, through debridement, forces the biofi lm phenotype community to continually reattach to the host, reform its extracellular polymeric substance, and increase its metabolic activity for cell division, synthesis and colony activity. Each of these factors provides a clinical opportunity as the biofi lm is more vulnerable to antibiotics and selective biocides during the recovery phase of the biofi lm postdebridement. Debridement as part of a multiple concurrent strategy for wound care is an effective tool for the suppression of biofi lm. ■
